AIDS

Journal

Publication Venue For

  • Cytomegalovirus (CMV)-Vectored vaccines for HIV and other pathogens. 2019
  • HIV stigma and viral load among African-American women receiving treatment for HIV.  33:1511-1519. 2019
  • HIV stigma and viral load among African-American women receiving treatment for HIV..  33:1511-1519. 2019
  • Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States.  33:1379-1384. 2019
  • Kidney disease in Africans with HIV and tuberculosis.  33:1207-1213. 2019
  • Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV: The mediating role of depression.  33:571-576. 2019
  • Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.  33:33-44. 2019
  • Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma 2019
  • Social Harms in Female-INITIATED hiv prevention method RESEARCH: State of the evidence 2019
  • Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer.  32:2821-2826. 2018
  • Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.  32:2507-2516. 2018
  • Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?.  32:2547-2556. 2018
  • Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?.  32:2547-2556. 2018
  • Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.  32:2017-2021. 2018
  • Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.  32:1279-1287. 2018
  • Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status..  32:1279-1287. 2018
  • Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio..  32:1361-1367. 2018
  • Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. 2018
  • Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation..  32:1389-1401. 2018
  • Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.  32:729-737. 2018
  • Trends in antiretroviral therapy prescription, durability and modification: New drugs, more changes, but less failure.  32:347-355. 2018
  • Virologic suppression and CD4 + cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.  32:261-266. 2018
  • Beyond binary retention in HIV care: Predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort.  32:2217-2225. 2018
  • HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.  32:2151-2159. 2018
  • Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract.  32:1571-1578. 2018
  • Racial differences in calculated bioavailable Vitamin D with Vitamin D/calcium supplementation.  31:2337-2344. 2017
  • Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.  31:1697-1707. 2017
  • CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.  31:1129-1136. 2017
  • Cervical cancer screening intervals and management for women living with HIV: A risk benchmarking approach.  31:1035-1044. 2017
  • Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care.  31:1009-1016. 2017
  • Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.  31:787-795. 2017
  • Smoking, HIV, and risk of pregnancy loss.  31:553-560. 2017
  • Interpreting the influence of race and cognitive activity on neurocognition in adults aging with HIV.  31:443-445. 2017
  • Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease.  31:199-205. 2017
  • Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.  30:1229-1238. 2016
  • Assessing efficacy of a retention-in-care intervention among HIV patients with depression, anxiety, heavy alcohol consumption and illicit drug use.  30:1111-1119. 2016
  • A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.  30:869-878. 2016
  • High rate of lymphoma among a UK cohort of adolescents with vertically acquired HIV-1 infection transitioning to adult care in the era of antiretroviral therapy.  30:153-156. 2016
  • A prospective study of anal cancer screening in HIV-positive and negative MSM.  30:1375-1383. 2016
  • Cost considerations in the current antiretroviral era.  30:2215-2219. 2016
  • Normal T-cell activation in elite controllers with preserved CD4 + T-cell counts.  29:2245-2254. 2015
  • Disclosure of pharmacokinetic drug results to understand nonadherence.  29:2161-2171. 2015
  • Intimate partner violence and engagement in HIV care and treatment among women: A systematic review and meta-analysis.  29:2183-2194. 2015
  • The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial.  29:1975-1986. 2015
  • Examining the association between male circumcision and sexual function: Evidence from a British probability survey.  29:1411-1416. 2015
  • Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.  29:947-954. 2015
  • Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients..  29:373-383. 2015
  • A better screening tool for HIV-associated neurocognitive disorders: Is it what clinicians need?.  29:895-902. 2015
  • Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.  29:1113-1115. 2015
  • Testosterone replacement therapy among HIV-infected men in the CFAR network of integrated clinical systems.  29:77-81. 2015
  • Mitochondrial DNA variation and virologic and immunological HIV outcomes in African Americans.  28:1871-1878. 2014
  • Decline in locomotor functions over time in HIV-infected patients.  28:1531-1532. 2014
  • Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.  28:979-987. 2014
  • Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings.  28:717-725. 2014
  • Deficient synthesis of class-switched, HIVneutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.  28:2201-2211. 2014
  • Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.  28:2627-2631. 2014
  • HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.  27. 2013
  • Association of early HIV viremia with mortality after HIV-associated lymphoma.  27:2365-2373. 2013
  • Clinical, radiological and laboratory features of human metapneumovirus lower respiratory tract infection in HIV-positive patients: A case series.  27:2317-2319. 2013
  • Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.  27:1593-1602. 2013
  • Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009..  27:803-813. 2013
  • Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.  27:221-225. 2013
  • Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.  26:2257-2259. 2012
  • Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero.  26:2053-2058. 2012
  • Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.  26:1907-1915. 2012
  • Replication of RYR3 gene polymorphism association with cIMT among HIV-infected whites.  26:1571-1573. 2012
  • Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.  26:731-740. 2012
  • The association between Mycoplasma genitalium and HIV-1 acquisition in African women..  26:617-624. 2012
  • Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'.  26:397-398. 2012
  • Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans.  26:229-234. 2012
  • The association between Mycoplasma genitalium and HIV-1 acquisition in African women.  26:617-624. 2012
  • Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).  25:2113-2122. 2011
  • IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.  25:2099-2104. 2011
  • Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy.  25:691-700. 2011
  • Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.  25:185-195. 2011
  • Virologic and immunologic response to HAART, by age and regimen class.  24:2469-2479. 2010
  • Periconception pre-exposure prophylaxis to prevent HIV transmission: Benefits, risks, and challenges to implementation.  24:1975-1982. 2010
  • Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.  24:1717-1726. 2010
  • Outcomes after virologic failure of first-line ART in South Africa.  24:1007-1012. 2010
  • A genome-wide association study of carotid atherosclerosis in HIV-infected men.  24:583-592. 2010
  • Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection.  24:573-582. 2010
  • A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.  24:447-455. 2010
  • HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation.  23:2255-2263. 2009
  • Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements..  23:2199-2208. 2009
  • Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.  23:1539-1546. 2009
  • HIV viremia and changes in kidney function.  23:1089-1096. 2009
  • Host genetics and HIV-1 viral load set-point in African-Americans.  23:673-677. 2009
  • Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.  23:525-530. 2009
  • Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes..  23:2069-2077. 2009
  • Does short-term virologic failure translate to clinical events in antiretroviral- naive patients initiating antiretroviral therapy in clinical practice 2008
  • Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.  22:1951-1960. 2008
  • Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.  22:1821-1827. 2008
  • Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline.  22:957-962. 2008
  • Association of antiretroviral therapy with fibrinogen levels in HIV-infection.  22:707-715. 2008
  • Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration (ART-CC).  22:2481-2492. 2008
  • Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.  21:2387-2397. 2007
  • Prevalence and factors associated with dry skin in HIV infection: The FRAM study.  21:2051-2057. 2007
  • Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems.  21:1821-1823. 2007
  • Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.  21:1373-1375. 2007
  • Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe.  21:1027-1034. 2007
  • Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.  21. 2007
  • Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic.  20:2115-2116. 2006
  • Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression.  20:1583-1590. 2006
  • Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.  20:1521-1529. 2006
  • Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.  20:1109-1116. 2006
  • Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.  20:353-360. 2006
  • Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.  20:223-231. 2006
  • Monocyte derived dendritic cells from HIV-1 infected individuals partially reconstitute CD4 T-cell responses.  20:171-180. 2006
  • Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy.  19:1439. 2005
  • A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.  19:1289-1297. 2005
  • Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.  19:1309-1315. 2005
  • Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.  19:1059-1063. 2005
  • Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals.  19:381-389. 2005
  • CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.  19:241-250. 2005
  • Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.  19:145-152. 2005
  • Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.  19:2174-2175. 2005
  • Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count.  19:2038-2041. 2005
  • Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study.  18:2391-2400. 2004
  • Factors associated with chronic renal failure in HIV-infected ambulatory patients..  18:2171-2178. 2004
  • Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.  18:939-943. 2004
  • Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.  17:1659-1665. 2003
  • Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents.  17:311-320. 2003
  • The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy..  17 Suppl 4. 2003
  • Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.  16:2275-2284. 2002
  • A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.  16:579-588. 2002
  • Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.  16:75-83. 2002
  • Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).  15:1971-1978. 2001
  • Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection.  15:335-339. 2001
  • Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.  14:2869-2876. 2000
  • Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884.  14:2495-2501. 2000
  • Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370.  14:1553-1561. 2000
  • Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine.  14:1365-1374. 2000
  • Short tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes.  14:1507-1513. 2000
  • Partner type and condom use.  14:537-546. 2000
  • Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy.  13:1677-1685. 1999
  • Predictors of optimal virological response to potent antiretroviral therapy.  13:1873-1880. 1999
  • Cerebrospinal fluid S-100b concentrations in patients with HIV infection [4].  13:139-140. 1999
  • HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women [10].  13:1990-1991. 1999
  • Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents.  13:1629-1635. 1999
  • Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults.  12. 1998
  • Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team..  12:F203-F209. 1998
  • The new HIV therapies: Implications for HIV prevention [6].  12:117-118. 1998
  • Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection.  11:289-295. 1997
  • Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients.  10:619-623. 1996
  • Cerebral proton magnetic resonance spectroscopy in cytomegalovirus encephalitis and HIV leucoencephalopathy/encephalitis [9].  10:1443-1444. 1996
  • Vitamin A depletion in HIV infection and AIDS [10].  10:114. 1996
  • Seroconversion in patients attending sexually transmitted disease clinics.  8:351-355. 1994
  • Persistent anaemia in HIV-infected individuals due to parvovirus B19 infection [6].  8:1191-1192. 1994
  • Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.  7. 1993
  • Expression of HIV-1 in the cerebrospinal fluid detected by the polymerase chain reaction and its correlation with central nervous system disease.  5:797-803. 1991
  • HTLV-I and HIV-1-associated neurologic abnormalities; syphilis as a confounding factor.  3:763-769. 1989
  • Reversible zidovudine-induced pure red-cell aplasia.  3:177-178. 1989
  • International Standard Serial Number (issn)

  • 0269-9370
  • Electronic International Standard Serial Number (eissn)

  • 1473-5571